Case Report: Effective management of adalimumab-induced acquired hemophilia A with the CyDRI protocol

• DOI: 10.3389/pore.2024.1611720
• Publication Date: 2024-05-23T04:11:52Z
• Authors: Andrea Ceglédi; Árpád Bátai; János Dolgos; Mónika Fekete; László Gopcsa; Viktória Király; Gergely Lakatos; György Nagy; Zsuzsanna Szemlaky; Andrea Várkonyi; Beáta Vilimi; Gábor Mikala; Imre Bodó
• Keywords: rheumatoid arthritis; Male; bleeding disorder; immunosuppression; acquired hemophilia A; Adalimumab; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Pathology and Oncology Archive; Factor VIIa; Hemophilia A; Recombinant Proteins; Arthritis, Rheumatoid; 03 medical and health sciences; 0302 clinical medicine; adalimumab; Antirheumatic Agents; Pathology; RB1-214; Humans; Rituximab; RC254-282; Aged; Retrospective Studies

Introduction Acquired Hemophilia A (AHA) is a rare autoimmune disorder characterized by the emergence of inhibitors that specifically target coagulation Factor VIII, frequently resulting in severe bleeding episodes. Methods We conducted retrospective analysis medical records 68-year-old male patient who presented with adalimumab-induced AHA. Results The received adalimumab, tumor necrosis factor inhibitor antibody, as part his treatment for rheumatoid arthritis. patient’s clinical journey, intense and coagulopathy, was effectively managed application recombinant VIIa (rFVIIa) CyDRi protocol. Discussion case emphasizes importance prompt assessment patients symptoms receiving disease-modifying therapy arthritis includes adalimumab therapy, considering yet life-threatening nature Additionally, this report provides an extensive review existing literature on drug-induced AHA, special emphasis cases linked to immunomodulatory medications. Through two-pronged approach, our aims enhance understanding awareness complication among healthcare providers, promoting timely diagnosis intervention.